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Sepsis is a complex syndrome resulting from a dysregulated immune response to an
infection. Due to the high prevalence, morbidity, and mortality, there is a lot of interest
in understanding pathways that play a role in sepsis, with a focus on the immune
system. Tumor necrosis factor (TNF) is a pleiotropic pro-inflammatory cytokine and a
master regulator of the immune system but clinical trials with TNF blockers in sepsis
have failed to demonstrate significant protection. Since TNF stimulates two different
receptors, TNF receptor 1 (TNFR1) and TNFR2, pan-TNF inhibition might be suboptimal
since both receptors have opposite functions in polymicrobial sepsis. Therefore, we
hypothesized that TNF has a dual role in sepsis, namely a mediating and a protective role,
and that protection might be obtained by TNFR1-specific inhibition. We here confirmed
that TNFR1−/− mice are protected in the sterile endotoxemia model, whereas TNFR1
deficiency did not protect in the cecal ligation and puncture (CLP)-induced polymicrobial
sepsis model. Since whole body TNFR1 blockage might be deleterious because of the
antibacterial function of TNF/TNFR1 signaling, we focused on the potential devastating
role of TNF/TNFR1 signaling in specific cell types. We were interested in the gut
epithelium, the endothelium, and hepatocytes using conditional TNFR1−/− mice, as
these cell types have been shown to play a role in sepsis. However, none of these
conditional knockout mice showed improved survival in the CLP model. We conclude
that cell-specific targeting of TNFR1 to these cell types has no therapeutic future in
septic peritonitis.
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INTRODUCTION
Sepsis is an acute condition resulting from a dysregulated host response to an infection. It is a
major cause of morbidity and mortality among hospitalized patients and the leading cause of death
among patients in intensive care units (ICUs). It is thought that up to 19 million cases arise yearly,
and that the overall mortality is about 20–25%, reaching up to 40% in case of septic shock. Sepsis
patients are usually treated with antibiotics, resuscitation, and organ function support. But despite
huge investments over the last 30–40 years into sepsis, no therapeutics have reached the bedside (1).
Vandewalle et al. Role of TNFR1 in Sepsis
Although sepsis is considered as an inflammatory condition,
numerous clinical trials targeting inflammatory mediators have
consistently failed in human sepsis patients. The reasons for
these failures are believed to reside in the complexity of sepsis
at the level of the patient, the infectious agent and the immune
response (2). In the past, the host’s immune response to an
external pathogen has been divided in two phases. An early phase
typically characterized by an overwhelming immune response
leading to an excessive production of cytokines, followed by a
compensation mechanism through which the patient enters an
immunosuppressive state (3). This is however not a systemic
phenomenon as the location of the immune cells greatly
influence their functional status. The concepts of “leukocyte
reprogramming” or “trained immunity” are a more appropriate
way of qualifying events associated with the anti-inflammatory
response. The ultimate goal of these mechanisms is probably
aimed at preventing an excessive pro-inflammatory response,
while maintaining the defense mechanisms (4).
The pro-inflammatory response is driven primarily by
cytokines and inflammatory mediators released by the innate
immune system. The pro-inflammatory cytokine tumor necrosis
factor (TNF), has long been considered as a top-candidate
mediator in sepsis patients and animals (5). Indeed, TNF
inhibition using antibodies protected in a model of Gram-
negative infection with live Escherichia coli (6). Conversely,
injection of recombinant TNF causes systemic inflammation in
humans and animals (7). However, up until now, 18 different
clinical trials using TNF inhibitors have been performed in sepsis
patients with very minimal impact on the survival rates (8).
TNF-induced lethal systemic inflammation was demonstrated
to depend entirely and exclusively on TNFR1 (9, 10). Since TNF
is able to bind and activate two different receptors, namely TNF
receptor 1 (TNFR1), generally considered as the inflammation-
mediating receptor, and TNFR2, considered as the immune
modulating receptor (11), we and others have argued that
TNF/TNFR1 inhibition should be considered in sepsis rather
than full TNF antagonism (12, 13).
To investigate this hypothesis, we applied a highly validated
mouse model of septic polymicrobial peritonits, namely cecal
ligation and puncture (CLP) (14), using conventional as well
as cell-specific TNFR1-deficient animals. We focused on cell-
specific deletion of TNFR1 in intestinal epithelial cells (IECs),
endothelial cells and hepatocytes. Our results reveal that neither
whole body nor cell-specific TNFR1 deficiency lead to significant
improvement of the survival rates upon CLP-induced sepsis
implicating that TNFR1 targeting is not a suitable treatment
strategy in sepsis.
RESULTS
TNFR1 Plays a Mediating Role in Lethal
Endotoxemia
In order to confirm the specific role of TNFR1 in acute
lethal endotoxemia, we investigated the response of whole body
TNFR1−/− mice and TNFR2−/− mice to a single intraperitoneal
injection of lipopolysaccharide (LPS), and compared it with
the response of Wild Type (WT) mice. This injection leads to
a lethal response, and we studied hypothermia and lethality
over a period of 150 h (no later deaths occurred). In agreement
with previous studies (15–17), we found that TNFR1−/− mice
were significantly more protected to both hypothermia and
lethality compared to WT (p < 0.0001) and TNFR2−/− animals
(p = 0.0007). In contrast, TNFR2−/− animals displayed no
protection (Figures 1A,B).
Full TNFR1−/− Mice Are Not Protected in
the CLP Model
As the LPS-induced model is a sterile model, this model does
not represent real polymicrobial sepsis. Therefore, we studied
the role of TNFR1 in the cecal ligation and puncture (CLP)
model. This is a more reliable and well-validated model for
sepsis, and the model is considered being the golden standard of
human peritonitis (14). First, we investigated the survival rate of
whole body TNFR1−/− mice subjected to CLP, and compared it
with WT mice. Figure 2A displays the general outcome of two
independent experiments, where we did not find any resistance
in TNFR1−/− mice compared to WT controls in this model.
The experiment was repeated using a sublethal CLP, but again
no difference in mortality betweenWT and TNFR1−/− mice was
observed (Figure 2B). Since TNF and TNFR1 have been found
to be important in antimicrobial defenses, a general absence of
TNFR1 might be a sensitizing factor in sepsis. To investigate
this role in polymicrobial sepsis, we determined the bacterial
counts in blood, peritoneal exudate and liver homogenate, 6 h
after CLP in TNFR1−/− and WT mice, and compared it with the
counts in sham-operated mice. In blood, we could not detect any
significant increase in colony forming units (CFU) when sham-
treated mice were compared with WT or TNFR1−/− mice that
were subjected to CLP (Figure 2C), although we detected a slight
trend toward higher bacterial counts in the TNFR1−/− mice. In
the peritoneal exudate and liver homogenate, the bacterial counts
in CLP-subjected TNFR1−/− mice were significantly higher than
in sham-operated mice, whereas we could not detect a significant
increase in CLP-subjected WT mice compared to sham mice
(Figures 2D,E). Based on the protection of TNFR1−/− mice in
sterile endotoxemia, but clear lack of protection in an infectious
sepsis model, it could be suggested that TNF/TNFR1 signaling
pathway is crucial in the clearance of bacteria upon sepsis and
thus has an indispensable function to cope with these bacteria.
Full TNFR1−/− Mice Exhibit Reduced LDH
and Vascular Permeability in the CLP
Model but Are Not Protected Against
Intestinal Permeability or Liver Damage
TNFR1 plays a mediating role in the sterile LPS model by
inducing injury in the liver (18), the gut barrier (19), and the
endothelium (20). Therefore, we studied the role of TNFR1 in
these organs in the CLP model. We detected decreased release
of lactate dehydrogenase (LDH) in plasma of the full TNFR1−/−
mice 8 h after CLP (Figure 3A), indicating reduced cell damage
or cell death. Since vascular hyperpermeability is a major feature
in SIRS and sepsis, we assessed the vascular permeability in full
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FIGURE 1 | Study of the effect of general TNFR1−/− in LPS-induced endotoxemia. (A,B) C57BL/6J wild type (WT) (n = 12), TNFR1−/− (n = 11), and TNFR2−/− mice
(n = 6) were intraperitoneally (i.p.) injected with a lethal dose of LPS (6.25 mg/kg). Body temperature (A) and lethality (B) were recorded. The last animals succumbed
52 h after challenge.
FIGURE 2 | Study of the effect of general TNFR1−/− in the cecal ligation and puncture model. (A,B) Male WT (n = 17) and TNFR1−/−(n = 16) were subjected to lethal
and sublethal CLP. All mice were treated with antibiotics 10 and 24 h after the CLP procedure. Survival was monitored for 10 days. (C–E) Six hours after CLP, blood
(C), peritoneal lavage fluid (D), and liver homogenate (E) were collected from sham-operated (n = 12) and lethal CLP WT (n = 12) and TNFR1−/− (n = 11) mice. Total
bacterial counts were determined and expressed as colony-forming units (CFU) per ml. *p ≤ 0.05 and ns, not significant.
TNFR1−/− and WT mice in the CLP model. FITC-dextran was
injected i.v. 5 h after CLP and vascular leakage was measured in
different organs (Figure 3B). CLP leads to a significant increase
in vascular permeability in all the organs tested (liver, lung,
kidney, heart, ileum, and spleen). Interestingly, there was a
constant tendency of reduced vascular leakage in TNFR1−/−
mice and this was significant in the lungs, kidney and spleen.
Next, increased intestinal permeability is also believed to play a
role in SIRS and sepsis. To investigate the role of TNFR1 in CLP
induced intestinal permeability, FITC-dextran was administered
by oral gavage 3 h after CLP and leakage of FITC-dextran from
the gut to the blood was measured. Intestinal permeability was
elevated after CLP, but no difference could be detected between
the two genotypes (Figure 3C). Lastly, liver damage has been
shown to occur in both SIRS and sepsis. Excessive TNF leads
to liver damage and elevated transaminase levels in circulation.
Alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) were significantly increased 8 h after CLP in both
genotypes, but were not significantly different between CLP-
subjected TNFR1−/− and WT mice (Figures 3D,E).
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FIGURE 3 | Study the role of TNFR1 on vascular, intestinal and liver damage in the cecal ligation and puncture model. Male WT and TNFR1−/− were subjected to
lethal CLP and following parameters were measured 8 h after CLP. (A) LDH was measured in plasma (n = 12/13). (B) Vascular permeability shown as relative light
units (RLU) of FITC-dextran in liver, lung, kidney, heart, ileum, and spleen after iv injection (n = 5/6). (C) Gut permeability shown as RLU of FITC-dextran in plasma after
gavage (n = 7–8). Aminotransferase levels (D) AST and (E) ALT levels were determined in plasma (n = 12–13). ****p < 0.0001, ***p < 0.001, **p < 0.01, *p ≤ 0.05
and ns, not significant.
TNFR1 Conditional Intestinal Epithelium,
Endothelial, and Hepatocyte Knockout
Mice Are Not Protected in CLP
It is possible that different cellular sources of TNFR1 mediate
different effects, and in order to distinguish the different
functionalities of TNF/TNFR1 signaling in different cell types,
we generated tissue-specific TNFR1-deficient mice by crossing
TNFR1flox/flox mice with three different cre lines. We reasoned
based on literature that the most obvious candidate cells that
would suffer the most from TNF in this model and sepsis in
general would be the intestinal epithelial cells (IECs), endothelial
cells and hepatocytes (21–23). After obtaining these cell-specific
conditional TNFR1−/− mice using Villin-, Tie2-, or albumin
cre lines, respectively, we subjected them to the CLP-induced
sepsis model and compared their response with that of the
TNFR1flox/flox control mice. As shown in Figures 4A–C, ablation
of TNFR1 in none of these tissues has a beneficial effect on
survival, and is therefore not of interest for therapeutic cell-
specific antagonism.
DISCUSSION
In 2016, a refined definition of sepsis has been accepted by
the community as the Third International Consensus Definition
for Sepsis and Septic Shock (Sepsis-3) (1). Now, sepsis is
defined as a life-threatening organ dysfunction caused by a
dysregulated host response to infection. In contrast to the Sepsis-
2 definition, this definition no longer refers to inflammation
as an essential pathway in sepsis (1). One of the reasons
of this adjustment is that the clinical trials testing inhibitors
of inflammatory cytokines have failed to provide significant
survival benefits, despite promising results in pre-clinical models
(2). This recurrent problem makes scientists wonder what the
community has missed or overlooked over the last decades.
There has been tremendous discussion about the use of pre-
clinical mouse models for studying acute inflammation in human
diseases. In 2013, Seok et al. identified a poor correlation of
the human and murine gene signatures in leukocytes after acute
inflammatory stresses, such as burn, trauma and endotoxemia,
thereby questioning the mouse as a research model (24). This
conclusion was however challenged by a reanalysis of these
same data but with restriction to the preselected genes that
significantly changed in both human and mice after insult
(25). The approach of the latter study is however controversial
as pre-selection of genes introduces bias (26). Yet, there are
substantial studies where animal models did predict the human
response to sepsis. Anti-TNF studies are life-saving in LPS-
induced SIRS models, but fail in septic patients, an argument
used in the debate against murine models. However, anti-TNF
antibodies used in a clinically more relevant model of sepsis,
the CLP model, also failed to show any protection, resembling
the human situation (27). This notion supports the need of
using the most relevant animal models and preferably testing
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FIGURE 4 | Study on the role of TNFR1 in endothelium, gut epithelium, and hepatocytes using conditional knock-out mice in the cecal ligation and puncture model.
Male TNFR1flox/flox and cell-specific conditional TNFR1−/− mice were subjected to CLP. Survival was monitored for 10 days in (A) endothelium (TNFR1Tie2−KO) (n = 8),
(B) gut epithelium (TNFR1Villin−KO) (n = 12) and (C) hepatocyte (TNFR1Alb−KO) specific (n = 12) knockout mice, and compared with TNFR1flox/flox mice (n = 9, 13, and
10, respectively).
in multiple types of infectious disease models (CLP-induced
peritonitis, pneumoniae).
Tumor necrosis factor (TNF) is a pleiotropic pro-
inflammatory cytokine and plays an important role in numerous
inflammatory diseases. TNF inhibiting drugs are powerful and
popular, and they revolutionized the treatment of rheumatoid
arthritis, Crohn disease, and psoriasis. However, TNF-inhibiting
biologicals can lead to a number of side effects (28). TNF can
bind and activate two different receptors, TNFR1 and TNFR2.
TNFR2 has been shown to be an immune-regulatory receptor,
which stimulates development of anti-inflammatory regulatory
T cells. Consequently, some authors believe that the side-effects
associated with the TNF inhibitors come from the abrogation
of the TNF/TNFR2 signaling in addition to the TNF/TNFR1
signaling (13). Studies using TNFR1−/− mice and TNFR2−/−
mice, as well as TNFR1-specific inhibitors have confirmed that
the aforementioned hypothesis might be true in some cases
(13). For example, in multiple sclerosis, TNF inhibition has no
therapeutic effect and could even lead to disease exacerbations,
whereas TNFR1 inhibition clearly has protective effects, as we
recently discovered using the Nanobody-based TNFR1-specific
inhibitor, called TNF Receptor One Silencer (TROS) (29).
Furthermore, we also showed therapeutic effect of TNFR1
inhibition using TROS in two different mouse models of
Alzheimer’s disease (30).
The current study was designed using the same reasoning.
TNF inhibition in sepsis patients has no obvious therapeutic
effect and a meta-analysis of all trials seems to suggest only
a minimal protective effect in the worst cases of septic shock
(8). These trials were a huge disappointment, particularly since
(i) early studies suggested promising effects of TNF-inhibiting
antibodies in a baboon sepsis model with Gram-negative
infection (6), (ii) TNF injections in animals and patients lead
to very similar pathophysiological responses as those observed
in sepsis (7), and (iii) several studies have found a link between
polymorphisms in the TNF promoter and susceptibility for sepsis
development (31).
A possible explanation for the failure of TNF inhibitors in
sepsis might be linked to the TNFR2 inhibition (12). Ebach et al.
showed that TNFR1−/− mice show prolonged survival in the
CLP model, whereas TNFR2−/− mice had shortened survival.
These data suggest that in sepsis, TNFR1 plays a mediating role
and TNFR2 rather a protective role (12). Moreover, we recently
reported that human sepsis patients display a significant increase
in levels of soluble TNFR1 and TNFR1 gene expression in blood
and blood cells, respectively (17). Additionally, simultaneous
inhibition of matrix metalloproteinase (MMP) 8 and TNFR1
protects against both endotoxemia and CLP-induced sepsis (17).
In our study, we tested TNFR1−/−mice in the CLPmodel, but no
differential response of TNFR1−/− mice in comparison to WT
mice was seen, while TNFR1 deficiency did show protection in
the endotoxemia model in agreement with other studies (9, 16).
In contrast, one study showed even sensitization of TNFR1−/−
mice in the CLP model (32). Overall, the exact role of TNFR1
in sepsis remains unclear. The differences observed in these
studies could result from different techniques used to induce
sepsis. There is quite some variation in the CLP procedure
resulting in different mortality and this could even contribute
to different results (33). The percentage of cecum that is ligated
and the number and size of punctures in the cecum are factors
contributing to the severity of CLP. Additionally, antibiotics,
the most important elements in the treatment of sepsis, are
not always included in animal studies. For example, the study
of Hildebrand et al. did not apply antibiotics, whereas in our
study antibiotics were provided to correlate better with the
human situation (32). Also the type of cecal bacteria involved
in the pathogenesis could be responsible for different mortality
and controversy in the CLP model. A recent paper showed
that commensal bacteria in the phylum Proteobacteria can
induce serum IgA, resulting in protection against CLP-induced
sepsis (34).
A second explanation for the failures of anti-TNF drugs
deals with the antimicrobial function of TNF. TNF knockout
as well as TNFR1 knockout mice have proven to be very
sensitive in infectious models, as the absence of TNF and TNFR1
leads to an inadequate innate immune response (13). When
studying the number of colony forming units following CLP,
we found a trend toward more contamination in blood of
TNFR1−/− mice compared to CLP-subjected WT mice. In the
peritoneal cavity and liver, significantly higher levels of colony
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forming units were found in CLP-subjected TNFR1−/− mice
compared to sham-operated mice, and this was not the case
for CLP-subjected WT mice. These data suggest that TNFR1
deficiency might undermine the antibacterial immunity, and that
therefore protective effects are lost. It has been shown previously,
that TNFR1−/− mice, indeed, suffer from significantly less
controlled bacterial infections, e.g., in models of Streptococcus or
Citrobacter (35). This reflection formed the basis to investigate
whether a depletion of TNFR1 on cells which are not involved
in the antibacterial immunity in the CLP model might lead to
improved survival rates. We chose to deplete TNFR1 in cells (i)
which are known to respond strongly to TNF, for example after
TNF injection (21) and (ii) which are believed to play a role in
sepsis (21–23), namely IECs, endothelial cells and hepatocytes.
These are cells that might be targeted by TNFR1-specific
inhibitors, such as TROS, linked with for example Nanobodies
that target specifically hepatocytes (asialoglycoprotein receptor)
or endothelium (VCAM1).
Our results illustrate the susceptibility of three different
organs toward organ damage in CLP-induced sepsis, namely
liver, gut, and endothelium. During SIRS and sepsis, these
organs are indeed known to be vulnerable for increased damage,
eventually resulting in multiple organ failure. Intestinal damage
accompanied by apoptosis and detachment of IECs are typical
features of TNF-induced SIRS, leading to gut barrier leakiness.
The gut has long been hypothesized to be “the motor” of
critical illness. Former research in our lab has shown that
intestinal TNFR1 plays a critical role in TNF-induced shock (21).
Reduction of TNFR1 expression specifically in IECs mitigates
TNF toxicity and this is linked with a reduction in TNF-
induced intestinal permeability and systemic inflammation (21).
However, Duprez et al. have shown that gut damage is not
immediately linked to mortality in TNF-induced SIRS. They
showed that Caspase 3−/− mice are protected against gut
damage, but these mice do not show improved survival (36).
The other way around holds also true, since RIPK3−/− mice and
Necrostatin-1 (a necroptosis inhibitor) pretreatment of WTmice
protect against TNF-induced lethality, but do not protect against
gut damage. In contrast, liver damage was significantly reduced in
these mice, indicating that liver damage might contribute to TNF
mortality (36). We studied liver and gut damage in TNFR1−/−
and WT mice after CLP but could not find a difference in
organ damage. This could explain the lack of protection in
respectively TNFR1AlbKO and TNFR1villinKO mice. In contrast,
vascular permeability was reduced in all organs tested in the
full TNFR1−/− mice. Specific deletion of TNFR1 in endothelial
cells however did also not protect against CLP induced lethality.
Our results could imply that cell-specific targeting of TNFR1 to
one of these three cell types has no future in sepsis, however,
a synergistic protection of TNFR1 in different organs together
could possibly still result in reduced mortality. Furthermore, we
studied the role of TNFR1 only in liver, gut and endothelium.
However, LDH release was significantly lower in TNFR1−/−mice
after CLP. Since LDH is released into the bloodstream when
tissues are damaged, it is plausible that TNFR1 plays a mediating
role in other organs than the three we tested. Themost significant
difference in vascular permeability was seen in the kidneys. As
acute kidney injury (AKI) occurs in 40–50% of the septic patients
and increases themortality risk 6- to 8-fold, it would be of interest
to study the role of TNFR1 in the kidneys in the CLP model.
The data presented here suggest that TNFR1 is an essential
mediator in endotoxemia, which is a mouse model of sterile
SIRS, induced by lipopolysaccharides. In a mouse model of
polymicrobial sepsis, induced by CLP, low grade inflammation is
induced by slow release of cecal content (bacteria, yeast, molds,
viruses etc.) into the peritoneum. This model is considered
as a useful model of septic peritonitis, which accounts for
∼30% of human sepsis cases (37). Based on the finding that
organism-wide TNFR1-deficiency has no differential response
in the CLP model, and based on the knowledge that TNFR1 is
essential in antimicrobial resistance, we tested the hypothesis that
retention of TNFR1 on peritoneal WBC, but depletion of TNFR1
on potential TNF-target cells, responding to the inflammatory
properties of TNF, may uncouple the beneficial from the harmful
effects of TNF in sepsis, as predicted in recent opinion pieces
(38). Our data suggest that cell-specific inhibition of TNFR1 in
hepatocytes, endothelium or intestinal epithelium provides no
therapeutic benefit in septic peritonitis.
MATERIALS AND METHODS
Mice
All mice were housed in specific-pathogen free conditions
with 14–10 h of light and dark cycles and free access to
food and water. We used 8–12 week old mice, females for
endotoxemia experiments, andmales for CLP experiments.Wild-
type, TNFR1−/− [generated by M Rothe (39)], and TNFR2−/−
animals (40), all on a pure C57BL/6J background were originally
purchased at the Jackson Laboratories, and further bred in our
animal house. TNFR1flox/flox mice, which were a kind gift from
Dr. G. Kollias (Alexander Fleming Biomedical Sciences Research
Center, Vari, Greece), were crossed with Villin-, Tie2-, or albumin
cre mice to generate, respectively, intestinal epithelial cell
(IEC), endothelial cell or hepatocyte-specific TNFR1 conditional
knockout mice (41).
Endotoxemia Model
Female mice were injected intraperitoneally with a lethal dose
of LPS [LD100 6.25 mg/kg, Salmonella enterica (Sigma-Aldrich)]
dissolved in sterile PBS to mimic endotoxin shock. Rectal body
temperature (first 24 h are shown) and lethality was monitored
and pooled from two independent experiments.
Cecal Ligation and Puncture (CLP) Induced
Polymicrobial Sepsis
The CLP procedure was performed according to the general
guidelines (14). Briefly, male mice were anesthetized by
isoflurane inhalation and a one-centimeter incision was made in
the abdomen after which the cecumwas exposed and ligated. This
was followed by making two punctures in the cecum with a 21-
Gauge needle for induction of a lethal CLP and one puncture
with a 23-Gauge needle for induction of a sublethal CLP.
The abdominal musculature and skin were closed with simple
running sutures and metallic clips, respectively. Ten and 24 h
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after CLP, mice were injected intraperitoneally with an antibiotic
cocktail containing ceftriaxone (25 mg/kg; Sigma-Aldrich) and
metronidazole (12.5 mg/kg; Sigma-Aldrich) dissolved in 200 µl
PBS. Rectal body temperature and lethality was monitored for 10
days and pooled.
Determination of Bacterial Load
Blood was taken via cardiac puncture after anesthetization with
a lethal mix of ketamine/xylazine and collected in EDTA-coated
tubes. Peritoneal fluid was taken by peritoneal lavage with 4mL
of PBS containing 1mM EDTA. 50mg liver was isolated and
homogenized in 600 µl PBS. Serial dilutions of blood, peritoneal
fluid or liver homogenate were prepared in sterile PBS for
plating on brain-heart-infusion agar plates. Plates were overnight
incubated at 37◦C. Viable counts of bacteria were expressed as
colony-forming units per ml blood.
LDH, ALT, AST in Blood
Eight hours after CLP or sham, blood was obtained via retro-
orbital bleeding, sampled in EDTA-coated tubes and plasma was
prepared (3,000 rpm, 20min, 4◦C). Plasma was diluted in 0.9%
NaCl and biochemical analysis was performed by the University
Hospital of Ghent.
Gut Permeability Assay
Three hours after CLP or sham, 100 µl of 100 mg/ml FITC-
dextran (4 kDa, Sigma-Aldrich) was gavaged. Five hours after
gavage, blood was obtained via retro-orbital bleeding, sampled
in EDTA-coated tubes and plasma was prepared (3,000 rpm,
20min, 4◦C). Plasma was diluted ½ in PBS and fluorescence
was measured with a FLUOstar OMEGA plate reader (BMG
Labtech, Germany).
Vascular Permeability Assay
Six hours after CLP or sham, 25 mg/kg FITC-dextran (4
kDa, Sigma-Aldrich) was injected intravenous. One hour later,
mice were anesthetized with a lethal mix of ketamine/xylazine
and transcardially perfused with 0.2% heparin in PBS. A
selected set of organs was isolated, cut in small pieces and
shaken overnight in 100% formamide (Sigma-Aldrich) at 37◦C
to extract FITC-labeled dextran from the tissue. After 18 h
incubation, the samples were centrifuged at 13,000 rpm for
15min and supernatant was diluted 1/20 in PBS and fluorescence
measured with a FLUOstar OMEGA plate reader (BMG Labtech,
Germany). Fluorescence was corrected for weight of the samples
and normalized to the lowest value.
Statistics
Data are represented as mean ± SEM. P-values for survival
curves were analyzed with a Log-rank test. P-values for all other
experiments were analyzed with one-way ANOVA. Data of two
independent experiments were pooled.
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